ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $36.50.
Separately, Laidlaw initiated coverage on ABIVAX Société Anonyme in a research note on Monday, July 29th. They issued a “buy” rating and a $48.00 target price on the stock.
View Our Latest Report on ABVX
Institutional Investors Weigh In On ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Performance
ABIVAX Société Anonyme stock opened at $10.45 on Thursday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The company’s fifty day simple moving average is $11.15 and its 200-day simple moving average is $12.80.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
- Five stocks we like better than ABIVAX Société Anonyme
- Business Services Stocks Investing
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Compound Interest and Why It Matters When Investing
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.